Last reviewed · How we verify
NCT07077083: CAIX PET/CT
CAIX PET/CT for Residual or Recurrent Post-ablative ccRCC
Phase 2 trial testing 89Zr-Girentuximab in Clear Cell Renal Cell Carcinoma (ccRCC) in 10 participants. Not yet recruiting.
1 August 2027
Quick facts
| Lead sponsor | Massachusetts General Hospital |
|---|---|
| Phase | Phase 2 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | diagnostic |
| Enrollment | 10 |
| Start date | 16 March 2026 |
| Primary completion | 1 August 2027 |
| Estimated completion | 1 August 2028 |
| Sites | 1 location across United States |
Drugs / interventions tested
- 89Zr-Girentuximab — full drug profile →
Conditions studied
- Clear Cell Renal Cell Carcinoma (ccRCC) — all drugs for Clear Cell Renal Cell Carcinoma (ccRCC) →
- ccRCC — all drugs for ccRCC →
Sponsor
Massachusetts General Hospital
Who can join
18 and older, any sex, with Clear Cell Renal Cell Carcinoma (ccRCC) or ccRCC. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The goal of this clinical trial is to learn whether 89Zr-Girentuximab PET scans can inform management of renal cell carcinoma. The main questions it aims to answer are: * Does the 89Zr-Girentuximab PET detect ccRCC that is left behind or has come back after treatment? * What differences can be seen on the 89Zr-Girentuximab PET before and after standard of care treatment? Participants in arm 1 will be given the study drug followed by a PET scan 3-7 days after injection. Participants in arm 2 will receive the same, but will proceed with their standard of care cryoablation after the initial PET scan. Within 3 days of the cryoablation treatment, participants will receive a repeat PET scan.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT07077083
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of 89Zr-Girentuximab
Trials testing the same drug.
- NCT05861778 — Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear · Phase 1 · completed
- NCT05046665 — Phase I Study to Evaluate the Diagnostic Performance of 89Zirconium Girentuximab PET in Urothelial Cancer Patients · Phase 1 · completed
- NCT03556046 — 89Zr-girentuximab ) Dosimetry in CCRC Study - ZIR-DOSE · Phase 1 · completed
Other recruiting trials for Clear Cell Renal Cell Carcinoma (ccRCC)
Currently open trials in the same condition.
- NCT07386158 — Pucotenlimab Combination With Vorolanib as Neoadjuvant Therapy for ccRCC · Phase 2 · recruiting
- NCT05176483 — Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors · Phase 1 · recruiting
- NCT03972657 — A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for A · Phase 1, PHASE2 · recruiting
- NCT03634540 — A Trial of Belzutifan (PT2977, MK-6482) in Combination With Cabozantinib in Patients With Clear Cell Renal Cell Carcinom · Phase 2 · active not recruiting
Other Massachusetts General Hospital trials
Trials by the same sponsor.
- NCT03585946 — Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis · withdrawn
- NCT07214831 — A Feasibility and Acceptability Study of a Large Language Model-based Chatbot for Brief Alcohol Intervention Among Emerg · NA · not yet recruiting
- NCT06686901 — A Randomized Controlled Trial of a Smartphone Delivered Treatment for Suicidal Thoughts and Behavior · NA · not yet recruiting
- NCT05854212 — Behavioral Economics to Implement Nutrition Ranking in Food Pantries · NA · not yet recruiting
- NCT07323446 — The MIND Study: The MGH/MIT Investigation of NAC on Dysregulation · EARLY_PHASE1 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07077083 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Massachusetts General Hospital
- Last refreshed: 11 March 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07077083.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing